Deucravacitinib: First Approval

DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study

(2022) S Danese et al.   Journal of Crohns & Colitis

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

(2022) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Deucravacitinib for the Treatment of Psoriatic Disease

(2022) Ana Maria Lé et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials

(2022) R. B. Warren et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

(2022) E. Morand et al.   ANNALS OF THE RHEUMATIC DISEASES

POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM

(2022) R. B. Warren et al.   ANNALS OF THE RHEUMATIC DISEASES

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

(2022) April W. Armstrong et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial

(2022) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

(2021) A. Armstrong et al.   ANNALS OF THE RHEUMATIC DISEASES

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

(2021) Anjaneya Chimalakonda et al.   Dermatology and Therapy

Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis

(2021) Ian M. Catlett et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

(2020) Miguel Nogueira et al.   DRUGS

349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease

(2018) Jenny H. Xie et al.   GASTROENTEROLOGY

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis

(2018) Kim Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY